Application of Physiologically Based Pharmacokinetic Modeling to Predict Drug-Drug Interactions between Elexacaftor/Tezacaftor/Ivacaftor and Tacrolimus in Lung Transplant Recipients

• Main Authors: Eunjin Hong (Author), Eugeniu Carmanov (Author), Alan Shi (Author), Peter S. Chung (Author), Adupa P. Rao (Author), Kevin Forrester (Author), Paul M. Beringer (Author)
• Formato: Libro
• Publicado: MDPI AG, 2023-05-01T00:00:00Z.
• Subjects: article
• Acceso en liña: Connect to this object online.

Elexacaftor/tezacaftor/ivacaftor (ETI) treatment has potential benefits in lung transplant recipients, including improvements in extrapulmonary manifestations, such as gastrointestinal and sinus disease; however, ivacaftor is an inhibitor of cytochrome P450 3A (CYP3A) and may, therefore, pose a risk...